Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

C3L-02654

· cohortA1

2efc13be-4f22-576a-af3b-104880578aab

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype
cohortA1
subtype
cohortA1
age_years
70.59000684

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.600
  • INTERFERON_GAMMA_RESPONSE+0.430
  • E2F_TARGETS+0.390
  • MTORC1_SIGNALING+0.280
  • G2M_CHECKPOINT+0.250
  • INFLAMMATORY_RESPONSE+0.240
  • SPERMATOGENESIS+0.200
  • GLYCOLYSIS+0.190
  • ALLOGRAFT_REJECTION+0.160
  • IL6_JAK_STAT3_SIGNALING+0.140

Top 10 suppressed

  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.440
  • WNT_BETA_CATENIN_SIGNALING-0.430
  • TGF_BETA_SIGNALING-0.400
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
  • MYC_TARGETS_V2-0.360
  • NOTCH_SIGNALING-0.320
  • APICAL_JUNCTION-0.310
  • HEDGEHOG_SIGNALING-0.310
  • UV_RESPONSE_DN-0.270
  • MYOGENESIS-0.240

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-55-A4DF-01A-11R-A24H-07
lung-landscapes@6
cohortA30.821
2SRR650131
bladder-landscape@3
0.809
3SRR4195655
colon-landscapes@1
0.802
4TCGA-A8-A08I-01A-11R-A00Z-07
breast-umap@18
C0.795
5SRR12202420
bladder-landscape@3
0.792
6SRR12475138
colon-landscapes@1
0.779
7SRR2016949
head-neck@1
0.779
8s0122212
melanoma-umap@29
0.761
91f57edd1-3bc9-4eaf-8045-8984d5c7f148
melanoma-umap@29
0.740
10SRR12475116
colon-landscapes@1
0.738

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 14 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.600Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.430Idelalisib— uncovered
E2F_TARGETS0.390Inavolisib— uncovered
MTORC1_SIGNALING0.280Inavolisib— uncovered
G2M_CHECKPOINT0.250Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.240Idelalisib— uncovered
SPERMATOGENESIS0.200Inavolisib— uncovered
GLYCOLYSIS0.190Inavolisib— uncovered
ALLOGRAFT_REJECTION0.160Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.140Inavolisib— uncovered
KRAS_SIGNALING_DN0.140Remibrutinib— uncovered
PROTEIN_SECRETION0.140Remibrutinib— uncovered
PANCREAS_BETA_CELLS0.130Cobimetinib— uncovered
KRAS_SIGNALING_UP0.120Inavolisib— uncovered